Cyclacel Pharmaceuticals (NASDAQ:BGMS) Announces Quarterly Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) announced its quarterly earnings results on Thursday. The company reported ($0.07) EPS for the quarter, FiscalAI reports. The company had revenue of $0.45 million during the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 31.60% and a negative net margin of 118.27%.

Cyclacel Pharmaceuticals Trading Down 4.2%

BGMS traded down $0.03 during trading on Friday, reaching $0.68. The stock had a trading volume of 4,960 shares, compared to its average volume of 720,752. The stock’s 50 day moving average is $0.89 and its two-hundred day moving average is $0.94. The company has a market capitalization of $4.50 million, a price-to-earnings ratio of -0.19 and a beta of -0.44. Cyclacel Pharmaceuticals has a one year low of $0.57 and a one year high of $2.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research note on Tuesday, October 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has an average rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. Its research programs are designed to target key proteins involved in tumor-cell growth, division and survival, with the goal of addressing cancers that have limited treatment options. The company’s pipeline has included fadraciclib (CYC065), an investigational selective cyclin-dependent kinase 2 inhibitor, and sapacitabine (CYC682), an oral nucleoside analog studied in several oncology indications.